Sintx Technologies (SINT) Current Deferred Revenue (2013 - 2018)
Sintx Technologies' (SINT) quarterly Current Deferred Revenue came in at $169000.0 in Q4 2018, up 196.49% quarter-over-quarter from $57000.0 in Q4 2014.
Sintx Technologies (SINT) Current Deferred Revenue (2013 - 2018) Analysis & Trends
Sintx Technologies' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $169000.0 for Q4 2018.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $169000.0 in Q4 2018; TTM through Dec 2018 was $169000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $169000.0, changed N/A from the prior year.
- Current Deferred Revenue improved to $169000.0 in Q4 2018 per SINT's latest filing, from $57000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $169000.0 in Q4 2018 and bottomed at $37000.0 in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Sintx Technologies | 17,274.80 | -1.87 Mn | 144,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 169,000.00 |
| Dec 31, 2014 | 57,000.00 |
| Sep 30, 2014 | 50,000.00 |
| Jun 30, 2014 | 43,000.00 |
| Mar 31, 2014 | 37,000.00 |
| Dec 31, 2013 | 32,000.00 |